Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 51.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 222,934 shares of the biopharmaceutical company’s stock after acquiring an additional 75,807 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Amicus Therapeutics were worth $2,381,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in FOLD. OLD Second National Bank of Aurora acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. grew its holdings in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. increased its position in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new position in shares of Amicus Therapeutics during the 3rd quarter worth approximately $32,000. Finally, Headlands Technologies LLC acquired a new stake in Amicus Therapeutics in the 2nd quarter valued at approximately $89,000.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 16th. Guggenheim upped their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Morgan Stanley cut their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. JPMorgan Chase & Co. raised their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Finally, Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 target price for the company. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $9.72 on Tuesday. The company has a fifty day moving average of $10.80 and a two-hundred day moving average of $10.59. The company has a market capitalization of $2.90 billion, a PE ratio of -28.59 and a beta of 0.68. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,901 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. This represents a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 30,401 shares of company stock valued at $352,038. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.